Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer presents CP-751,871 study results

Pfizer presents CP-751,871 study results

16th September 2008

Pfizer has presented the safety and efficacy results of a study of CP-751,871 at the annual congress European Society for Medical Oncology in Stockholm, Sweden.

The company presented the results of a phase II randomised, non-comparative study of the compound in patients with non-small cell lung cancer (NSCLC).

In total, 54 per cent of patients with stage III/IV treatment-naive NSCLC treated with the compound in addition to carboplatin and paclitaxel showed objective responses, up from 41 per cent in patients treated with carboplatin and paclitaxel alone.

Furthermore, 78 per cent of patients with squamous cell carcinoma and 57 per cent of those with adenocarcinoma showed a response to CP-751,871 plus carboplatin and paclitaxel, with response rates of 46 per cent and 25 per cent respectively.

Luis Paz-Ares, chief of the division of medical oncology at the Virgen del Rocio University Hospital in Seville, Spain, said: “These data contribute to our evolving understanding of the potential safety and efficacy of CP-751,871 in patients with NSCLC, a devastating disease.”

He added that an estimated 1.5 million new cases of NSCLC are expected worldwide in 2008, with limited treatment options available for this disease.

In June 2007, Pfizer said three of its oncology compounds would enter phase III of clinical development this year, including CP-751,871, Sutent and Axitinib.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.